Rep. Gilbert Ray Cisneros, Jr. Buys Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Ultragenyx Pharmaceutical stock on March 3rd. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of StandardAero (NYSE:SARO) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of FirstService (NASDAQ:FSV) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Advanced Energy Industries (NASDAQ:AEIS) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Flex (NASDAQ:FLEX) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of LPL Financial (NASDAQ:LPLA) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 3/27/2026.
• Purchased $15,001 – $50,000 in shares of Fabrinet (NYSE:FN) on 3/27/2026.

Ultragenyx Pharmaceutical Trading Up 2.4%

Ultragenyx Pharmaceutical stock traded up $0.55 during trading on Thursday, reaching $23.70. The company had a trading volume of 694,273 shares, compared to its average volume of 2,382,704. The firm has a market capitalization of $2.33 billion, a price-to-earnings ratio of -4.06 and a beta of 0.25. The firm’s 50-day simple moving average is $22.11 and its 200 day simple moving average is $27.64. Ultragenyx Pharmaceutical Inc. has a 52 week low of $18.29 and a 52 week high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The company had revenue of $207.28 million for the quarter, compared to the consensus estimate of $199.60 million. During the same period in the prior year, the firm posted ($1.39) EPS. The business’s revenue for the quarter was up 25.5% on a year-over-year basis. On average, analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Several institutional investors and hedge funds have recently modified their holdings of RARE. Assetmark Inc. grew its stake in Ultragenyx Pharmaceutical by 1,706.7% during the third quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 1,024 shares in the last quarter. Huntington National Bank lifted its stake in Ultragenyx Pharmaceutical by 56.2% in the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 393 shares in the last quarter. Danske Bank A S bought a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter valued at about $39,000. Smartleaf Asset Management LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 205.4% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 1,169 shares during the last quarter. Finally, Covestor Ltd grew its position in shares of Ultragenyx Pharmaceutical by 26.0% during the third quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 369 shares in the last quarter. Institutional investors own 97.67% of the company’s stock.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Eric Crombez sold 7,029 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $160,261.20. Following the completion of the transaction, the executive vice president owned 76,301 shares in the company, valued at $1,739,662.80. This trade represents a 8.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Howard Horn sold 4,683 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $20.97, for a total value of $98,202.51. Following the completion of the sale, the chief financial officer directly owned 80,351 shares in the company, valued at approximately $1,684,960.47. The trade was a 5.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 109,556 shares of company stock valued at $2,490,138. 5.50% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts recently issued reports on RARE shares. JPMorgan Chase & Co. cut their price objective on Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating for the company in a research note on Thursday, March 12th. Leerink Partners lowered their price target on shares of Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Tuesday, December 30th. HC Wainwright reduced their price objective on shares of Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th. Canaccord Genuity Group decreased their price objective on shares of Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating on the stock in a research report on Wednesday, February 18th. Finally, Jefferies Financial Group lowered their target price on shares of Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating on the stock in a research note on Tuesday, December 30th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $60.47.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.